Midazolam Accord

What Is Midazolam Accord and What Is It Used For?

Midazolam Accord is a short-acting injectable benzodiazepine that produces sedation, anxiety relief, muscle relaxation, and amnesia. It is used for conscious sedation during procedures, intensive care sedation, general anaesthesia induction, and premedication before surgery.

Midazolam belongs to the benzodiazepine class of medications, a group of drugs that enhance the activity of gamma-aminobutyric acid (GABA) in the brain. GABA is the main inhibitory neurotransmitter in the central nervous system (CNS), and by boosting its effects, midazolam produces a calming, sedative influence on brain activity. This mechanism makes it highly effective for inducing a state of relaxation, drowsiness, or sleep while also reducing anxiety and muscle tension.

Unlike many other benzodiazepines, midazolam is classified as short-acting, meaning its effects begin rapidly and wear off relatively quickly. When administered intravenously, the onset of sedation typically occurs within 2 to 3 minutes, and when given intramuscularly, effects are usually apparent within 15 minutes. This pharmacokinetic profile makes midazolam particularly well-suited for medical procedures that require a brief period of sedation followed by a relatively rapid recovery.

Midazolam Accord is manufactured by Accord Healthcare and is available in two concentrations: 1 mg/ml and 5 mg/ml solution for injection or infusion. The product is supplied in glass ampoules and, in some formulations, prefilled syringes. Other brand names for midazolam include Midazolam Accordpharma and Midazolam hameln.

Approved Clinical Uses

Midazolam Accord is approved for the following indications, each of which leverages its sedative, anxiolytic, and amnestic properties:

• Conscious sedation (procedural sedation): Used in both adults and children to induce a relaxed, calm, and drowsy state during diagnostic or therapeutic procedures such as endoscopy, dental procedures, minor surgical interventions, and catheterisations. The patient remains awake but deeply relaxed and typically has limited memory of the procedure afterwards.
• Intensive care sedation: Administered as a continuous infusion to maintain sedation in critically ill patients who require mechanical ventilation or other intensive care interventions. Both adults and children may receive this form of sedation.
• General anaesthesia induction: In adults, midazolam can be used alone or in combination with other anaesthetic agents to induce general anaesthesia before surgical procedures. It is frequently combined with opioid analgesics and neuromuscular blocking agents.
• Premedication: Given before anaesthesia to produce relaxation, calmness, and drowsiness in both adults and children. Premedication with midazolam helps reduce preoperative anxiety and facilitates a smoother induction of anaesthesia.

What Should You Know Before Taking Midazolam Accord?

Midazolam is contraindicated in patients with known allergy to benzodiazepines and in patients with severe respiratory insufficiency undergoing conscious sedation. Special caution is required in elderly patients, those with chronic organ disease, and children under 6 months.

Contraindications

Midazolam Accord must not be administered in the following circumstances:

• Allergy to midazolam or any excipient: If you have previously experienced an allergic reaction to midazolam or any of the inactive ingredients (sodium chloride, sodium hydroxide, hydrochloric acid, water for injections), you must not receive this medication.
• Allergy to other benzodiazepines: Cross-sensitivity may exist between benzodiazepines. If you are allergic to other benzodiazepines such as diazepam (Valium) or nitrazepam, you should not be given midazolam.
• Severe respiratory problems during conscious sedation: If you have severe respiratory insufficiency and midazolam is planned for conscious sedation (rather than in a fully monitored ICU or anaesthesia setting), the drug must not be used because of the risk of further respiratory depression.

Warnings and Precautions

Your healthcare team should be informed of the following conditions before midazolam is administered, as they may affect dosing, monitoring requirements, or the decision to use this medication:

For adults:

• Age over 60 years: Elderly patients are significantly more sensitive to the effects of midazolam and are at higher risk of respiratory depression, excessive sedation, and cardiovascular effects. Doses should be reduced and titrated carefully.
• Chronic medical conditions: Patients with chronic respiratory disease (such as COPD), kidney disease, liver disease, or heart disease may metabolise midazolam differently and require adjusted dosing. Liver impairment is particularly relevant because midazolam is primarily metabolised by the liver.
• Debilitated patients: Those who are physically weakened by illness require lower doses and more careful monitoring.
• Obstructive sleep apnoea: Patients with this condition are at increased risk of airway obstruction during sedation and must be monitored closely.
• Myasthenia gravis: This neuromuscular disorder can be worsened by benzodiazepines, which have muscle-relaxant properties.
• Alcohol use: Regular or excessive alcohol consumption can potentiate the CNS depressant effects of midazolam, potentially leading to profound sedation, coma, or death. Inform your doctor about your alcohol habits.
• History of substance abuse: Patients with a history of drug or alcohol dependence may be at increased risk of developing dependence on midazolam.

For children and infants:

• Cardiovascular conditions in children require special attention, as midazolam may affect heart rate and blood pressure. The dose must be individually adjusted.
• Infants under 6 months should only receive midazolam for ICU sedation, and continuous monitoring of breathing and oxygen levels is mandatory.
• All children receiving midazolam must be closely monitored throughout the procedure and during recovery.

Pregnancy and Breastfeeding

Midazolam should only be used during pregnancy when clearly necessary and no safer alternative is available. The risks vary by trimester:

• Early pregnancy: Midazolam may potentially harm the developing foetus. Animal studies have shown reproductive toxicity, though human data are limited.
• Late pregnancy and delivery: When high doses are given near delivery or during caesarean section, the mother may be at risk of aspiration, and the newborn may experience irregular heart rhythm, floppy muscle tone (hypotonia), feeding difficulties, hypothermia, and respiratory depression.
• Prolonged use in late pregnancy: Extended administration may cause the foetus to develop physical dependence, leading to neonatal withdrawal symptoms after birth.
• Breastfeeding: Midazolam passes into breast milk. Breastfeeding should be avoided for at least 24 hours after receiving midazolam.

Driving and Operating Machinery

Midazolam causes drowsiness, dizziness, impaired concentration, coordination problems, and amnesia. These effects can persist for several hours after administration. You must not drive a vehicle, operate machinery, or perform tasks requiring alertness until you have fully recovered. Your doctor will advise you when it is safe to resume these activities. You must always be accompanied home by a responsible adult after receiving midazolam for a procedure.

Sodium Content

Midazolam Accord contains less than 1 mmol (23 mg) of sodium per ampoule, making it essentially sodium-free. This is relevant for patients on sodium-restricted diets.

How Does Midazolam Accord Interact with Other Drugs?

Midazolam has clinically significant interactions with many medications. CYP3A4 inhibitors increase its blood levels and sedative effects, CYP3A4 inducers decrease its effectiveness, and CNS depressants potentiate the risk of excessive sedation and respiratory depression.

Midazolam is primarily metabolised by the cytochrome P450 enzyme CYP3A4 in the liver. This means that any medication which inhibits or induces CYP3A4 can significantly alter midazolam blood levels, potentially leading to either excessive sedation or reduced therapeutic efficacy. Additionally, any drug that depresses the central nervous system can have additive or synergistic effects when combined with midazolam.

It is critically important to inform your doctor about all medications you are taking, including prescription drugs, over-the-counter medicines, and herbal supplements. The following table summarises the most important drug interactions:

Major Interactions (CYP3A4 Inhibitors — Increased Midazolam Effect)

CYP3A4 Inducers (Decreased Midazolam Effect)

CNS Depressant Interactions

The following drug classes have additive CNS-depressant effects when combined with midazolam and increase the risk of excessive sedation, respiratory depression, and haemodynamic instability:

• Opioid analgesics (morphine, fentanyl, codeine) — highest risk; may cause life-threatening respiratory depression
• Other benzodiazepines and sedatives/hypnotics — cumulative sedation
• Antidepressants and antipsychotics — enhanced CNS depression
• Antihistamines (especially first-generation sedating types) — additive drowsiness
• Alcohol — potentially fatal enhancement of respiratory depression
• Methyldopa — enhanced sedative effect

What Is the Correct Dosage of Midazolam Accord?

Midazolam doses are individually titrated based on the clinical indication, patient age, body weight, health status, and response. It must only be administered by experienced healthcare professionals in facilities with resuscitation capabilities. The drug is given intravenously, intramuscularly, or rectally.

Midazolam dosing is highly individualised. Your doctor determines the exact dose based on the reason for use, the type and depth of sedation required, your weight, age, general health, concurrent medications, and your response to the initial dose. If strong analgesics (pain medications) are also needed, these are typically administered first, and the midazolam dose is then carefully titrated.

Routes of Administration

Midazolam Accord can be given by four different routes:

• Slow intravenous (IV) injection: The most common route for procedural sedation and anaesthesia induction. Allows precise titration.
• Intravenous (IV) infusion: Used for continuous sedation in intensive care settings via a drip or syringe pump.
• Intramuscular (IM) injection: Used when IV access is not available or for premedication.
• Rectal administration: Primarily used in children as premedication when IV access is not established.

Adults

Children

Elderly

Patients aged 60 years and above require significantly reduced doses because of increased sensitivity to benzodiazepines, reduced hepatic clearance, and higher risk of adverse effects. Conscious sedation should begin at 0.5 to 1 mg IV with slow titration. Anaesthesia induction doses should not exceed 0.15 mg/kg. Careful monitoring of respiratory and cardiovascular function is essential throughout.

Overdose

As midazolam is always administered by healthcare professionals, overdose in routine practice is uncommon but possible, particularly if the drug is given too rapidly or in excessive doses. Symptoms of midazolam overdose may include:

• Excessive drowsiness and prolonged sedation
• Loss of coordination (ataxia) and absent reflexes
• Slurred speech (dysarthria)
• Involuntary eye movements (nystagmus)
• Low blood pressure (hypotension)
• Respiratory arrest (apnoea) and cardiorespiratory depression
• Coma in severe cases

What Are the Side Effects of Midazolam Accord?

Like all medications, midazolam can cause side effects. The most clinically significant are respiratory depression, cardiovascular depression, and paradoxical reactions. Many reported side effects have no established frequency and are listed as "frequency not known".

Side effects of midazolam range from mild and transient to rare but potentially life-threatening. The risk of serious adverse events is significantly higher in elderly patients, patients with pre-existing respiratory or cardiovascular disease, and when the injection is given too rapidly or at excessive doses. Below is a comprehensive overview categorised by frequency and organ system.

Populations at Higher Risk

• Adults over 60: Life-threatening side effects (respiratory depression, cardiac arrest) are more likely, especially with rapid injection or high doses.
• Patients with pre-existing respiratory or cardiac conditions: Increased vulnerability to cardiovascular and respiratory adverse events.
• Patients with severe kidney disease: More likely to experience side effects due to impaired drug elimination.
• Children and elderly: Higher incidence of paradoxical reactions (agitation, aggression, hallucinations).

Tolerance, Dependence, and Withdrawal

Prolonged use of midazolam, particularly in ICU settings, can lead to tolerance (reduced drug effect) and physical dependence. If midazolam is stopped abruptly or the dose is reduced too quickly after prolonged administration, withdrawal symptoms may occur:

• Headache, diarrhoea, and muscle pain
• Severe anxiety, tension, restlessness, confusion, and irritability
• Mood changes and insomnia
• Hallucinations and seizures
• In severe cases: depersonalisation, numbness and tingling in extremities, hypersensitivity to light, sound, and touch

To prevent withdrawal, your doctor will gradually reduce the midazolam dose (tapering) rather than stopping it abruptly.

How Should You Store Midazolam Accord?

Midazolam Accord should be stored in the original packaging to protect from light, kept out of the reach of children, and not used after the expiry date. Storage is the responsibility of healthcare professionals.

Under normal circumstances, patients will not need to store Midazolam Accord themselves, as it is administered in hospital and clinic settings. However, the following storage information is important for proper drug handling:

• Keep out of sight and reach of children.
• Do not use after the expiry date printed on the ampoule label and outer carton (after "EXP"). The expiry date refers to the last day of the stated month.
• Store ampoules in the original packaging to protect from light (midazolam is photosensitive).
• Ampoules are for single use only. Any unused solution must be discarded.
• After dilution: The diluted solution is chemically and physically stable for 24 hours at room temperature (15-25°C) or 3 days at 2-8°C. From a microbiological standpoint, the product should be used immediately after opening.
• Disposal: Unused medication should be disposed of according to local pharmaceutical waste regulations. Do not dispose of via household waste or wastewater.

What Does Midazolam Accord Contain?

The active substance is midazolam (as midazolam hydrochloride). Inactive ingredients include sodium chloride, sodium hydroxide, hydrochloric acid, and water for injections.

Active Ingredient

Midazolam Accord 1 mg/ml: Each ml of solution contains 1 mg midazolam (as midazolam hydrochloride). A 5 ml ampoule contains 5 mg midazolam.

Midazolam Accord 5 mg/ml: Each ml of solution contains 5 mg midazolam (as midazolam hydrochloride). Available in 1 ml (5 mg), 3 ml (15 mg), and 10 ml (50 mg) ampoules.

Inactive Ingredients (Excipients)

• Water for injections
• Sodium chloride
• Sodium hydroxide (for pH adjustment)
• Concentrated hydrochloric acid (for pH adjustment)

Appearance and Pack Sizes

Midazolam Accord is a clear, colourless to pale yellow solution supplied in transparent glass ampoules within blister/tray packaging.

• 1 mg/ml: Packs of 10 x 5 ml ampoules
• 5 mg/ml: Packs of 10 x 1 ml, 10 x 3 ml, 1 x 10 ml, and 10 x 10 ml ampoules

Not all pack sizes may be marketed in all countries.

Manufacturer

Marketing Authorisation Holder: Accord Healthcare B.V., Winthontlaan 200, 3526 KV Utrecht, Netherlands.

Manufacturers: Accord Healthcare Polska Sp.z o.o., Pabianice, Poland; Accord Healthcare Single Member S.A., Schimatari, Greece.